{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:31:08Z","timestamp":1790958668429,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ecl.2022.02.011","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:37:25Z","timestamp":1656920245000},"page":"603-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Dyslipidemia in Diabetes"],"prefix":"10.1016","volume":"51","author":[{"given":"Ronald B.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2022.02.011_bib1","series-title":"Diabetes in America","article-title":"Heart disease and diabetes","author":"Barrett-Connor","year":"2018"},{"key":"10.1016\/j.ecl.2022.02.011_bib2","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2337\/dc11-1162","article-title":"Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey","volume":"35","author":"Gregg","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.ecl.2022.02.011_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.diabet.2009.04.004","article-title":"Lipid disorders in type 1 diabetes","volume":"35","author":"Verg\u00e8s","year":"2009","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ecl.2022.02.011_bib5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.amjcard.2015.08.039","article-title":"Metabolic dyslipidemia and risk of coronary heart disease in 28,318 adults with diabetes mellitus and low-density lipoprotein cholesterol <100\u00a0mg\/dl","volume":"116","author":"Rana","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib6","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2337\/dc19-0501","article-title":"Residual hypertriglyceridemia and estimated atherosclerotic cardiovascular disease risk by statin use in U.S. adults with diabetes: National Health and Nutrition Examination Survey 2007-2014","volume":"42","author":"Fan","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib7","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1210\/jc.2018-01656","article-title":"Association between triglyceride level and glycemic control among insulin-treated patients with type 2 diabetes","volume":"104","author":"Zheng","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2022.02.011_bib8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc08-0494","volume":"32","author":"Goldberg","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib9","doi-asserted-by":"crossref","first-page":"582826","DOI":"10.3389\/fcvm.2020.582826","article-title":"Clinical approach to assessment and amelioration of atherosclerotic vascular disease in diabetes","volume":"7","author":"Goldberg","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ecl.2022.02.011_bib11","doi-asserted-by":"crossref","first-page":"593931","DOI":"10.3389\/fendo.2020.593931","article-title":"A\u00a0comprehensive update on the chylomicronemia syndrome","volume":"11","author":"Goldberg","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ecl.2022.02.011_bib12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.2337\/dc16-2523","article-title":"DCCT\/EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial\/epidemiology of diabetes interventions and complications (DCCT\/EDIC) Study","volume":"40","author":"Purnell","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/diacare.26.5.1374","article-title":"Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study","volume":"26","author":"Orchard","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib14","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2022.02.011_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11886-015-0607-7","article-title":"Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges","volume":"17","author":"Gore","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ecl.2022.02.011_bib17","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Emerging risk factors collaboration: diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.02.011_bib18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2337\/diacare.29.04.06.dc05-1433","article-title":"High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database","volume":"29","author":"Soedamah-Muthu","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib19","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-008-1076-y","article-title":"Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database","volume":"51","author":"Mulnier","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.ecl.2022.02.011_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","article-title":"Type 2 diabetes in adolescents and young adults","volume":"6","author":"Lascar","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2022.02.011_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(15)00508-2","article-title":"Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study","volume":"4","author":"Huo","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2022.02.011_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.0686","article-title":"Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood","volume":"317","author":"Dabelea","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2022.02.011_bib23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2337\/dc13-1755","article-title":"Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults","volume":"37","author":"Kalyani","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib24","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/diacare.19.5.419","article-title":"Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients","volume":"19","author":"Connolly","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11606-015-3556-3","article-title":"Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events","volume":"31","author":"Rana","year":"2016","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib27","doi-asserted-by":"crossref","first-page":"i5953","DOI":"10.1136\/bmj.i5953","article-title":"Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis","volume":"355","author":"Huang","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2022.02.011_bib28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib29","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jama.2014.1873","article-title":"Glycated hemoglobin measurement and prediction of cardiovascular disease","volume":"311","author":"Di Angelantonio","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2022.02.011_bib30","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Diabetes control and complications trial\/epidemiology of diabetes interventions and complications (DCCT\/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2337\/diacare.27.3.781","article-title":"Insulin Resistance Atherosclerosis Study Investigators: Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study","volume":"27","author":"Rewers","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2337\/dc08-0025","article-title":"Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study","volume":"31","author":"Fox","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2337\/dci19-0036","article-title":"The 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes","volume":"43","author":"Goldberg","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacl.2011.06.011","article-title":"High-density lipoprotein cholesterol in diabetes: is higher always better?","volume":"5","author":"Costacou","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.ecl.2022.02.011_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdiacomp.2014.08.011","article-title":"High HDL-C prevalence is common in type 1 diabetes and increases with age but is lower in Hispanic individuals","volume":"29","author":"Alessa","year":"2015","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.ecl.2022.02.011_bib38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2022.02.011_bib39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/met.2014.0050","article-title":"Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance","volume":"12","author":"Shalaurova","year":"2014","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.ecl.2022.02.011_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MED.0000000000000597","article-title":"Lipoprotein (a) and diabetes mellitus: causes and consequences","volume":"28","author":"Ward","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ecl.2022.02.011_bib41","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.03.009","article-title":"Prospective association between diabetic retinopathy and cardiovascular disease\u2014a systematic review and meta-analysis of cohort studies","volume":"25","author":"Guo","year":"2016","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ecl.2022.02.011_bib42","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/heartjnl-2014-305657","article-title":"Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus","volume":"100","author":"Brownrigg","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.ecl.2022.02.011_bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1479164113500798","article-title":"Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register","volume":"10","author":"Svensson","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ecl.2022.02.011_bib44","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2008-2534","article-title":"Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications","volume":"94","author":"Goldberg","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2022.02.011_bib45","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ecl.2022.02.011_bib46","first-page":"e1046","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2022.02.011_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2022.02.011_bib48","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2165\/11638240-000000000-00000","article-title":"Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis","volume":"72","author":"de Vries","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ecl.2022.02.011_bib49","doi-asserted-by":"crossref","first-page":"996","DOI":"10.2337\/dc15-2450","article-title":"Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes","volume":"39","author":"Hero","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2022.02.011_bib50","first-page":"S125","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib51","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib52","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc11-0816","article-title":"Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis","volume":"34","author":"Malik","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib53","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jcmg.2019.01.014","article-title":"DCCT\/EDIC Research Group. The association of coronary artery calcification with subsequent incidence of cardiovascular disease in type 1 diabetes: the DCCT\/EDIC Trials","volume":"12","author":"Budoff","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.011_bib54","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacc.2021.07.025","article-title":"That myalgia of yours is not from statin intolerance","volume":"78","author":"Toth","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib55","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.011_bib56","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","article-title":"Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study","volume":"181","author":"Mansi","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.06.023","article-title":"Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance","volume":"306","author":"Soran","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2022.02.011_bib58","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2022.02.011_bib59","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2022.02.011_bib61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2022.02.011_bib62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/dom.12909","article-title":"Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub-analysis of ODYSSEY COMBO II","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ecl.2022.02.011_bib63","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib64","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.117.028503","volume":"135","author":"Virani","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2022.02.011_bib65","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.168.14.1531","article-title":"Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy","volume":"168","author":"Goldberg","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib66","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CRD.0000000000000401","article-title":"Bempedoic acid: a new avenue for the treatment of dyslipidemia","volume":"29","author":"Smith","year":"2021","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.ecl.2022.02.011_bib67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12933-020-01101-9","article-title":"Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis","volume":"19","author":"Wang","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ecl.2022.02.011_bib69","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.2337\/dc12-2455","article-title":"Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes","volume":"36","author":"Constantino","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib70","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.2337\/dc19-1758","article-title":"An early-onset subgroup of type 2 diabetes: a multigenerational, prospective analysis in the Framingham Heart Study","volume":"43","author":"Echouffo-Tcheugui","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib71","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacc.2015.11.021","article-title":"Statin initiation during childhood in patients with familial hypercholesterolemia: consequences for cardiovascular risk","volume":"67","author":"Braamskamp","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib72","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/db05-1423","article-title":"The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study Experience","volume":"55","author":"Pambianco","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2022.02.011_bib73","first-page":"1370","article-title":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Research Group. Risk factors for cardiovascular disease in type 1 diabetes","volume":"65","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2022.02.011_bib74","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1479164112436403","article-title":"Global cardiovascular disease risk assessment in United States adults with diabetes","volume":"9","author":"Wong","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ecl.2022.02.011_bib75","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.amjcard.2017.02.023","article-title":"Presence, characteristics, and volumes of coronary plaque determined by computed tomography angiography in young type 2 diabetes mellitus","volume":"119","author":"Nezarat","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib76","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc17-2233","article-title":"Duration of diabetes and prediabetes during adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: the CARDIA Study","volume":"41","author":"Reis","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/diacare.26.2.433","article-title":"Delineation of prevalence and risk factors for early coronary artery disease by electron beam computed tomography in young adults with type 1 diabetes","volume":"26","author":"Starkman","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib78","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2337\/dc19-0998","article-title":"Diabetes is associated with worse long-term outcomes in young adults after myocardial infarction: the Partners YOUNG-MI Registry","volume":"43","author":"Divakaran","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib79","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.ecl.2022.02.011_bib80","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.028271","article-title":"Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials","volume":"135","author":"Ridker","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2022.02.011_bib81","first-page":"1","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2022.02.011_bib82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J\u00a0Cardiovasc Risk"},{"key":"10.1016\/j.ecl.2022.02.011_bib83","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2022.02.011_bib84","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10654-006-9096-8","volume":"22","author":"Danesh","year":"2007","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ecl.2022.02.011_bib85","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2022.02.011_bib86","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF00265546","article-title":"Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study","volume":"32","author":"Fontbonne","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.ecl.2022.02.011_bib87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2022.02.011_bib88","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.13537","article-title":"Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol","volume":"21","author":"Nichols","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ecl.2022.02.011_bib89","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.02.011_bib90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib91","doi-asserted-by":"crossref","first-page":"e3473","DOI":"10.1210\/clinem\/dgab360","article-title":"Rare variants in triglycerides-related genes increase pancreatitis risk in multifactorial chylomicronemia syndrome","volume":"106","author":"Paquette","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2022.02.011_bib92","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/dci19-0064","article-title":"Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes","volume":"43","author":"Cusi","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2022.02.011_bib93","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ecl.2022.02.011_bib94","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib95","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ecl.2022.02.011_bib96","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11936-011-0128-7","article-title":"The use of fibric acid derivatives in cardiovascular prevention","volume":"13","author":"Khoury","year":"2011","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib97","first-page":"1849","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus","volume":"365","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.02.011_bib98","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Friedewald","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib99","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.02.011_bib100","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ecl.2022.02.011_bib101","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Pisano","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib102","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.ecl.2022.02.011_bib103","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ecl.2022.02.011_bib104","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ecl.2022.02.011_bib105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/FJC.0b013e3181b0cf71","article-title":"Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects","volume":"54","author":"Roth","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.ecl.2022.02.011_bib106","first-page":"S1933","article-title":"Update on the omega-3 fatty acid trial landscape: a narrative review with implications for primary prevention","author":"Kapoor","year":"2021","journal-title":"J\u00a0Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.011_bib107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.011_bib108","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.02.011_bib109","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:47:20Z","timestamp":1760176040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852922000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0889852922000263"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2022.02.011","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dyslipidemia in Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2022.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}